9 Promising Cardio Technologies: Improved Diagnostics

Improved Diagnostics

Abbott Laboratories's Architect Stat High-Sensitive Troponin-I (hsTnl) test could prevent unnecessary hospitalizations for patients who go to the emergency room with chest pain.

Better diagnostics lead to better treatment, and with heart disease killing one in four people in the United States, the race is on to fortify our frontline defenses against this deadly disease.

Progress is being made. Last year FDA cleared Diadexus's PLAC Test for Lp-PLA2 Activity, which can predict a person's risk of heart disease even if they've never experienced a cardiac event. Cleveland Clinic spinout Cleveland HeartLab is also developing a test to measure levels of trimethylamine-N-oxide (TMAO), a chemical produced in the gut that can contribute to cardiovascular disease.  

On the flip side, a new high-sensitivity test from Abbott Laboratories, The Architect Stat High-Sensitive Troponin-I (hsTnl), may help rule out heart attack in patients who go to the hospital with chest pains. 

[Image courtesy of ABBOTT LABORATORIES]

Learn how to design innovative structural heart therapies at the MD&M Minneapolis conference on September 21, 2016.